The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Influence of concurrent medications on PSA doubling time (PSADT) in patients (pts) with nonmetastatic biochemically relapsed prostate cancer (BRPC M0) after local therapy (tx).
Wilmosh Mermershtain
No relevant relationships to disclose
Maya Ish-Shalom
No relevant relationships to disclose
Natalie Maimon
No relevant relationships to disclose
Maya Gottfried
No relevant relationships to disclose
Keren Rouvinov
No relevant relationships to disclose
Roberto Pili
No relevant relationships to disclose
Hans J. Hammers
No relevant relationships to disclose
Victoria J. Sinibaldi
No relevant relationships to disclose
Michael Anthony Carducci
No relevant relationships to disclose
Mario A. Eisenberger
No relevant relationships to disclose
Daniel Keizman
No relevant relationships to disclose